All Articles

The Importance of MSI/dMMR as Biomarkers in Oncology
The Importance of MSI/dMMR as Biomarkers in Oncology
Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series
Genotyping tumors for microsatellite instability (MSI) has taken on new importance in the world of oncology. MSI screening has long been recognized as important in the care of patients with colorectal cancer (CRC) or endometrial cancer, and high-level MSI (MSI-H) is now being recognized as a potential marker for germline mutations in certain DNA mismatch-repair (MMR) genes that lead to the development of Lynch syndrome.
Read More
Clinical Relevance and Rationale of MSI-H/dMMR as a Biomarker in Patients with Cancer
Clinical Relevance and Rationale of MSI-H/dMMR as a Biomarker in Patients with Cancer
Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series
Previously, testing for microsatellite instability (MSI) or mismatch repair deficiency (dMMR) has been performed as a screening test to identify patients with Lynch syndrome in colorectal and endometrial cancer, in addition to providing prognostic and predictive data in colorectal cancer (CRC).
Read More
Achieving the Mission: Promoting Evidence-Based Navigation Practices
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Letters from Lillie
November 2018 Vol 9, NO 11
This time of year is one of great excitement for us at JONS and the Academy of Oncology Nurse & Patient Navigators (AONN+).
Read More
Factors Associated with Adherence to Risk Management for Women with a BRCA Mutation
By Kathryn A. Pratt, BSN, RN, OCN, CBCN; Jillian Huang, MS, MPH, CGC
AONN+ Conference Abstracts, Community Outreach and Prevention
November 2018 Vol 9, NO 11
Individuals with hereditary breast and ovarian cancer syndrome (HBOC), caused by mutations in BRCA1 and BRCA2, have some of the highest cancer incidences of any known group.
Read More
Testing Telephone-Based Patient Navigation for Lung Cancer Screening in an Integrated Safety Net System
By Simon Craddock Lee, PhD, MPH; Heidi A. Hamann, PhD; Magalis Z. Tijerina, BA; Cynthia Ortiz, MPH; Claudia Chavez, MBA; Noel Santini, MD; David E. Gerber, MD
AONN+ Conference Abstracts, Community Outreach and Prevention
November 2018 Vol 9, NO 11
While adherence to annual screening exceeded 90% in the National Lung Screening Trial, the trial population was disproportionately white, educated, and received care in the tightly controlled environment of a clinical trial.
Read More
Care Navigation Curbs Emergency Department Visits at Rush University Medical Center
By Ashley M. Prentice; Catherine Nwileh-Ibeagha
AONN+ Conference Abstracts, Coordination of Care/Care Transitions
November 2018 Vol 9, NO 11
In June 2016, Rush University Cancer Center (RUCC) entered into an agreement with the Centers for Medicare & Medicaid Services (CMS) to participate in the Oncology Care Model (OCM).
Read More

Page 187 of 281

Journal of Oncology Navigation & Survivorship

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

Connect with Us

 
 
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.